The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
Open accessAbstract
Aim: The efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods: In this randomized, double‐blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26‐week, placebo‐controlled, core period and a 26‐week, active‐controlled extension in which placebo‐treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double‐blind and control for safety). Safety data are reported for canagliflozin and placebo/sitagliptin. Results: Canagliflozin 100 and 300 mg significantly lowered haemoglobin A1c (HbA1c) compared with placebo at week 26 (−0.89%, −1.03% and −0.26%; p < 0.001); reductions with canagliflozin 100 and 300 mg were maintained at week 52 (−0.92% and −1.03%). Relative to placebo, both canagliflozin doses significantly reduced body weight (−2.5 and −3.5 kg), fasting plasma glucose and systolic blood pressure (BP) at week 26 (p < 0.05 for all), with reductions maintained at week 52. Overall adverse event (AE) incidence over 52 weeks was 69.9, 76.3 and 76.5% with canagliflozin 100 and 300 mg and placebo/sitagliptin; AE‐related discontinuation and serious AE rates were low. Incidences of genital mycotic infections and AEs related to osmotic diuresis and volume depletion were higher with canagliflozin than placebo/sitagliptin. Conclusion: Canagliflozin improved glycaemic control, reduced body weight and systolic BP, and was generally well tolerated in patients with T2DM on metformin and pioglitazone over 52 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationThe Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Stenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614
Self-citationBergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013) · Diabetologia · doi:10.1007/s00125-013-3039-1 · Cited by 492
Self-citationEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J. ‐., Bakris, G., Cariou, B., Yue, D., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12090 · Cited by 487
Self-citation
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454
Self-citationSchofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0167-x · Cited by 417
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
“Data were sorted by first author, year of publication, country of the study, design, age range of the participants, total sample size, SGLT2 inhibitor, comparator, number of patients, dosage, and follow-up duration (Table 1).(13-55)”
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Self-citationSGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Yale, J. ‐., Bakris, G., Cariou, B., Nieto, J., David‐Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12348 · Cited by 273
Self-citationBilezikian, J. P., Watts, N. B., Usiskin, K., Polidori, D., Fung, A., Sullivan, D., & Rosenthal, N. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1860 · Cited by 273
Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12825 · Cited by 253
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Wan, N., Rahman, A., Hitomi, H., & Nishiyama, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00421 · Cited by 115
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12589 · Cited by 91
Self-citationSinclair, A. J., Bode, B., Harris, S., Vijapurkar, U., Shaw, W., Desai, M., & Meininger, G. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14028 · Cited by 87
Self-citationSeidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
Cai, X., Gao, X., Yang, W., Chen, Y., Zhang, S., Zhou, L., Han, X., & Ji, L. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12760 · Cited by 64
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., Rosenstock, J., Capuano, G., Desai, M., Shaw, W., et al. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0117-z · Cited by 44
Self-citationDorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01103-9 · Cited by 39
Odutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29
Metadata
- Authors
- Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., & Stein, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-03-12
- Volume
- 16
- Issue
- 5
- Pages
- 467-477
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1982905493
- Cited by
- 255
- References
- 29
- FWCI
- 37.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.